- Q1'24 net revenue of $982 million decreased 4% as reported,
or 6% in constant currency(1), compared to Q1'23. Organic,
constant-currency net revenue decreased by 8%, compared to
Q1'23.
- Q1'24 net revenue, excluding COVID revenue of ~$185 million
in Q1’23 and ~$100 million in Q1’24, increased 5% compared to
Q1'23.
- Q1'24 net loss of $(715) million, includes non-cash goodwill
impairment charges of $700 million.
- Q1'24 Adjusted EBITDA(1) of $115 million decreased 38% as
reported, or 39% in constant currency, compared to Q1'23.
- Reaffirming FY'24 financial guidance range, which includes
net revenue of $4.3 billion to $4.5 billion and Adjusted EBITDA(1)
of $680 million to $760 million.
(1) See "Non-GAAP Financial Measures" below and the GAAP to
non-GAAP reconciliation provided later in this release.
Catalent, Inc. (NYSE: CTLT), the leader in enabling the
development and supply of better treatments for patients worldwide,
today announced preliminary financial results for the first quarter
of fiscal 2024, which ended September 30, 2023.
“As Catalent continues to execute our strategy to enhance value
for our stakeholders, the strength of our internal pipeline and our
solid first quarter financial performance give us the confidence to
reiterate our guidance for the full year,” said Alessandro Maselli,
President and Chief Executive Officer of Catalent, Inc. “We
continue to make strides towards improving our operations and
bringing our performance back to pre-COVID levels. We remain the
partner of choice for our customers’ most complex manufacturing
needs and continue to work to complete strategic capital
investments that will address the surging demand from patients in
high-growth areas, including capacity for sterile pre-filled
syringes.”
First Quarter 2024 Consolidated Results
Net revenue of $982 million decreased 4% as reported, or 6% in
constant currency, from the $1.02 billion reported for the first
quarter a year ago. Overall organic net revenue (i.e., excluding
the effect of acquisitions, divestitures, and currency translation)
decreased by 8% over the same period.
Net loss and loss per basic and diluted share was $(715)
million, or $(3.94) per basic and diluted share, compared to net
earnings of $0 million, or $0.00 per basic and diluted share, in
the first quarter a year ago. Net loss for the three months ended
September 30, 2023, includes non-cash goodwill impairment charges
of $700 million and incorporates the effect of a $29 million
deferred tax adjustment.
EBITDA (loss) from operations(1) was $(636) million, a decrease
of $770 million from the $134 million reported in the first quarter
a year ago. First quarter fiscal 2023 Adjusted EBITDA(1) was $115
million, or 11.7% of net revenue, compared to $187 million, or
18.3% of net revenue, in the first quarter a year ago. This
represents a decrease of 38% as reported and a decrease of 39% on a
constant-currency basis, compared to the fiscal 2023 period.
Adjusted Net Loss(1) was $(19) million, or $(0.10) per diluted
share, compared to Adjusted Net Income(1) of $61 million, or $0.34
per diluted share, in the first quarter a year ago.
(1)
See "Non-GAAP Financial Measures"
below and the GAAP to non-GAAP reconciliation provided later in
this release.
First Quarter 2024 Segment Review
(Dollars in millions)
Three Months Ended
September 30,
Constant
Currency
2023(3)
2022
Change %
Biologics
Net revenue
$
447
$
523
(16
)%
Segment EBITDA
52
113
(54
)%
Segment EBITDA margin
11.6
%
21.5
%
Pharma and Consumer Health
Net revenue
535
499
5
%
Segment EBITDA
101
108
(9
)%
Segment EBITDA margin
18.9
%
21.7
%
Unallocated costs (2)
(789
)
(87
)
*
Combined totals
Net revenue
$
982
$
1,022
(6
)%
EBITDA (loss) from operations
$
(636
)
$
134
*
(2)
For the three months ended
September 30, 2023, unallocated costs include $700 million of
non-cash goodwill impairment charges.
(3)
Represents preliminary
results.
*
Not meaningful
Biologics segment
2023 vs. 2022
Year-Over-Year Change
Three Months Ended
September 30,
Net Revenue
Segment
EBITDA
Organic
(16
)%
(54
)%
Constant-currency change
(16
)%
(54
)%
Foreign exchange translation impact on
reporting
1
%
—
%
Total % change
(15
)%
(54
)%
Pharma and Consumer Health
segment
2023 vs. 2022
Year-Over-Year Change
Three Months Ended
September 30,
Net Revenue
Segment
EBITDA
Organic
(1
)%
(19
)%
Impact of acquisitions
6
%
10
%
Constant-currency change
5
%
(9
)%
Foreign currency translation impact on
reporting
2
%
3
%
Total % change
7
%
(6
)%
Segment Net Revenue as a % of
Total Net Revenue
Three Months Ended
September 30,
2023*
June 30, 2023*
March 31, 2023
December 31, 2022
September 30,
2022
Biologics
46
%
38
%
46
%
50
%
51
%
Pharma and Consumer Health
54
%
62
%
54
%
50
%
49
%
Net Revenue
100
%
100
%
100
%
100
%
100
%
*Represents preliminary
results.
Balance Sheet and Liquidity
As of September 30, 2023, Catalent had $4.95 billion in total
debt, and $4.74 billion in total debt net of cash, cash
equivalents, and marketable securities, compared to $4.57 billion
in total net debt as of June 30, 2023.
Catalent's ratio of First Lien Debt over LTM Adjusted EBITDA was
3.4x at September 30, 2023. Catalent's senior secured credit
agreement requires that this ratio remain below 6.5x.
Catalent’s net leverage ratio(1) as of September 30, 2023 was
7.4x, compared to 6.4x at June 30, 2023 and 3.2x as of September
30, 2022.
(1)
See "Non-GAAP Financial Measures"
below and the GAAP to non-GAAP reconciliation provided later in
this release.
Fiscal Year 2024 Outlook
Management is reaffirming its previously issued financial
guidance for Fiscal Year 2024.
FY'24
Full-Year Guidance
Net revenue
$4,300 million - $4,500
million
Adjusted EBITDA
$680 million - $760 million
Adjusted net income
$113 million - $175 million
Weighted average shares
outstanding - diluted
181 million - 183 million
Earnings Webcast
The Company’s management will host a webcast to discuss the
results at 8:15 a.m. ET today. Catalent invites all interested
parties to listen to the webcast, which will be accessible through
Catalent’s website at http://investor.catalent.com. A supplemental
slide presentation will also be available in the “Investors”
section of Catalent’s website prior to the start of the webcast.
The webcast replay, along with the supplemental slides, will be
available for 90 days in the “Investors” section of Catalent’s
website at www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is the global leader in enabling
pharma, biotech, and consumer health partners to optimize product
development, launch, and full life-cycle supply for patients around
the world. With broad and deep scale and expertise in development
sciences, delivery technologies, and multi-modality manufacturing,
Catalent is a preferred industry partner for personalized
medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,500 partner programs and launch
over 150 new products every year. Its flexible manufacturing
platforms at over 50 global sites supply approximately 70 billion
doses of nearly 8,000 products annually. Catalent’s expert
workforce of nearly 18,000 includes more than 3,000 scientists and
technicians. Headquartered in Somerset, New Jersey, the company
generated nearly $4.3 billion in revenue in its 2023 fiscal year.
For more information, visit www.catalent.com.
Annual Report on Form 10-K and Quarterly Report on Form
10-Q
On November 13, 2023, the Company filed with the Securities and
Exchange Commission (“SEC”) a Notification of Late Filing on Form
12b-25, as it determined it would be unable to file its Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30, 2023
(the “Form 10-Q”) by its original due date of November 9, 2023, and
did not expect to file the Form 10-Q on or before the expiration of
the five calendar day extension period provided in Rule 12b-25 of
the Securities Exchange Act of 1934, as amended. The Company
continues to dedicate significant resources to the completion of
procedures related to management’s assessment of the effectiveness
of its internal controls over financial reporting as of June 30,
2023 and other closing procedures related to the Annual Report on
Form 10-K for the fiscal year ended June 30, 2023 (the “2023 Form
10-K”). The Company also requires additional time to complete its
procedures related to management’s assessment of the measurement
and timing of the non-cash goodwill impairment discussed herein,
and other closing procedures related to the Form 10-Q. The Company
is working diligently to complete the necessary work to file the
2023 Form 10-K and currently expects to file the Form 10-Q promptly
following the filing of the 2023 Form 10-K.
Non-GAAP Financial Measures
Use of EBITDA from operations, Adjusted EBITDA, Adjusted Net
Income and Segment EBITDA
Management measures operating performance based on consolidated
earnings from operations before interest expense, expense (benefit)
for income taxes, and depreciation and amortization, adjusted for
the income or loss attributable to non-controlling interests
(“EBITDA from operations”). EBITDA from operations is not defined
under U.S. GAAP, is not a measure of operating income, operating
performance, or liquidity presented in accordance with U.S. GAAP,
and is subject to important limitations.
Catalent believes that the presentation of EBITDA from
operations enhances an investor’s understanding of its financial
performance. Catalent believes this measure is a useful financial
metric to assess its operating performance across periods by
excluding certain items that it believes are not representative of
its core business and uses this measure for business planning
purposes.
In addition, given the significant investments that Catalent has
made in the past in property, plant and equipment, depreciation and
amortization expenses represent a meaningful portion of its cost
structure. Catalent believes that EBITDA from operations will
provide investors with a useful tool for assessing the
comparability between periods of Catalent's ability to generate
cash from operations sufficient to pay taxes, to service debt and
to undertake capital expenditures because it eliminates
depreciation and amortization expense. Catalent presents EBITDA
from operations in order to provide supplemental information that
it considers relevant for the readers of its consolidated financial
statements, and such information is not meant to replace or
supersede U.S. GAAP measures. Catalent’s definition of EBITDA from
operations may not be the same as similarly titled measures used by
other companies.
Catalent evaluates the performance of its segments based on
segment earnings before non-controlling interest, other (income)
expense, impairments, restructuring costs, interest expense, income
tax expense (benefit), and depreciation and amortization (“segment
EBITDA”). Moreover, under Catalent’s credit agreement, its ability
to engage in certain activities, such as incurring certain
additional indebtedness, making certain investments and paying
certain dividends, is tied to ratios based on Adjusted EBITDA,
which is not defined under U.S. GAAP, is not a measure of operating
income, operating performance, or liquidity presented in accordance
with U.S. GAAP, and is subject to important limitations. Adjusted
EBITDA is the covenant compliance measure used in the credit
agreement governing debt incurrence and restricted payments.
Because not all companies use identical calculations, Catalent’s
presentation of Adjusted EBITDA may not be comparable to similarly
titled measures of other companies.
Management also measures operating performance based on Adjusted
Net Income and Adjusted Net Income per share. Adjusted Net Income
is not defined under U.S. GAAP, is not a measure of operating
income, operating performance, or liquidity presented in accordance
with U.S. GAAP and is subject to important limitations. Catalent
believes that the presentation of Adjusted Net Income and Adjusted
Net Income per share enhances an investor’s understanding of its
financial performance. Catalent believes these measures are a
useful financial metric to assess its operating performance across
periods by excluding certain items that it believes are not
representative of its core business and Catalent uses these
measures for business planning purposes. Catalent defines Adjusted
Net Income as net earnings adjusted for amortization attributable
to purchase accounting and adjustments for other cash and non-cash
items included in the table below, partially offset by its estimate
of the tax effects of such cash and non-cash items. Catalent
believes that Adjusted Net Income and Adjusted Net Income per share
provides investors with a useful tool for assessing the
comparability between periods of its ability to generate cash from
operations available to its stockholders. Catalent’s definition of
Adjusted Net Income may not be the same as similarly titled
measures used by other companies. Adjusted Net Income per share is
computed by dividing Adjusted Net Income by the weighted average
diluted shares outstanding.
The most directly comparable U.S. GAAP measure to EBITDA from
operations, Adjusted EBITDA, and Adjusted Net Income is net
earnings. Included in this release is a reconciliation of net
earnings to EBITDA from operations, Adjusted EBITDA and Adjusted
Net Income.
Catalent does not provide a reconciliation of forward-looking
non-GAAP financial measures to their comparable U.S. GAAP financial
measures because it could not do so without unreasonable effort due
to the unavailability of the information needed to calculate
reconciling items and due to the variability, complexity and
limited visibility of the adjusting items that would be excluded
from the non-GAAP financial measures in future periods. When
planning, forecasting, and analyzing future periods, Catalent does
so primarily on a non-GAAP basis without preparing a U.S. GAAP
analysis as that would require estimates for various cash and
non-cash reconciling items that would be difficult to predict with
reasonable accuracy. For example, equity compensation expense would
be difficult to estimate because it depends on Catalent’s future
hiring and retention needs, as well as the future fair market value
of its common stock, all of which are difficult to predict and
subject to constant change. It is equally difficult to anticipate
the need for or magnitude of a presently unforeseen one-time
restructuring expense or the values of end-of-period foreign
currency exchange rates. As a result, Catalent does not believe
that a U.S. GAAP reconciliation would provide meaningful
supplemental information about its outlook.
Use of Constant Currency
As changes in exchange rates are an important factor in
understanding period-to-period comparisons, Catalent believes the
presentation of results on a constant-currency basis in addition to
reported results helps improve investors’ ability to understand its
operating results and evaluate its performance in comparison to
prior periods. Constant-currency information compares results
between periods as if exchange rates had remained constant period
over period. Catalent uses results on a constant-currency basis as
one measure to evaluate its performance. Catalent calculates
constant currency by calculating current-year results using
prior-year foreign currency exchange rates. Catalent generally
refers to such amounts calculated on a constant-currency basis as
excluding the impact of foreign exchange or being on a
constant-currency basis. These results should be considered in
addition to, not as a substitute for, results reported in
accordance with U.S. GAAP. Results on a constant-currency basis, as
Catalent presents them, may not be comparable to similarly titled
measures used by other companies and are not measures of
performance presented in accordance with U.S. GAAP.
Forward-Looking Statements
This release contains both historical and forward-looking
statements and guidance. All statements other than statements of
historical fact, are, or may be deemed to be, forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements generally can
be identified by the use of statements that include phrases such as
“believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,”
“project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,”
“target,” “will,” “would,” or other words or phrases with similar
meanings. Similarly, statements that describe Catalent’s
objectives, plans, or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent’s expectations, projections, and
guidance. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: the
finalization of Catalent’s fiscal 2023 and first quarter fiscal
2024 financial statements, the completion of Catalent’s closing
procedures, including without limitation its evaluation of the
effectiveness of its internal controls over financial reporting,
Catalent’s first quarter fiscal 2024 final results differing
materially from the preliminary results set forth herein, the final
timing of filing Catalent’s Annual Report on Form 10-K for the
fiscal year ended June 30, 2023 and the Quarterly Report on Form
10-Q for the fiscal quarter ended September 30, 2023 with the SEC;
Catalent’s ability to resolve productivity issues at three of its
manufacturing facilities, the impact of such issues on product made
at these facilities, the timing of recovering unproduced batches
and resumption of normal activities at these facilities, and the
impact of such issues on Catalent’s results of operations and
financial condition; the declining demand for various vaccines and
treatments for the SARS-Co-V-2 strain of coronavirus and its
variants (“COVID-19”) from both patients and governments around the
world may affect sales of the COVID-19 products Catalent
manufactures; participation in a highly competitive market and
increased competition that may adversely affect Catalent’s
business; demand for its offerings, which depends in part on its
customers’ research and development and the clinical and market
success of their products; product and other liability risks that
could adversely affect Catalent’s results of operations, financial
condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide
quality offerings to customers could have an adverse effect on
Catalent’s business and subject it to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to Catalent’s operations, including risks from
inflation, disruptions to global supply chains, or from the
Ukrainian-Russian war; inability to enhance existing or introduce
new technology or service offerings in a timely manner; inadequate
patents, copyrights, trademarks and other forms of intellectual
property protections; fluctuations in the costs, availability, and
suitability of the components of the products Catalent
manufactures, including active pharmaceutical ingredients,
excipients, purchased components and raw materials; changes in
market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S.
dollar against other currencies; adverse tax legislative or
regulatory initiatives or challenges or adjustments to Catalent’s
tax positions; loss of key personnel; risks generally associated
with information systems; inability to complete any future
acquisition or other transaction that may complement or expand its
business or divest of non-strategic businesses or assets and
difficulties in successfully integrating acquired businesses and
realizing anticipated benefits of such acquisitions; risks
associated with timely and successfully completing, and correctly
anticipating the future demand predicted for, capital expansion
projects at existing facilities; offerings and customers’ products
that may infringe on the intellectual property rights of third
parties; environmental, health, and safety laws and regulations,
which could increase costs and restrict operations; labor and
employment laws and regulations or labor difficulties, which could
increase costs or result in operational disruptions; additional
cash contributions required to fund Catalent’s existing pension
plans; substantial leverage that may limit its ability to raise
additional capital to fund operations and react to changes in the
economy or in the industry; exposure to interest-rate risk to the
extent of its variable-rate debt preventing it from meeting its
obligations under its indebtedness; and the impact of and risks
related to impairment losses with respect to goodwill or other
assets and the possibility that we may incur additional impairment
charges, including at Catalent’s Biomodalities and Consumer Health
reporting units. For a more detailed discussion of these and other
factors, see the information under the caption “Risk Factors” in
Catalent’s Annual Report on Form 10-K for the fiscal year ended
June 30, 2023. All forward-looking statements speak only as of the
date of this release or as of the date they are made, and Catalent
does not undertake to update any forward-looking statement,
including without limitation, any financial projection or guidance,
as a result of new information, future events, developments, or
otherwise, except to the extent required by law.
More products. Better treatments. Reliably
supplied.™
Catalent, Inc.
Consolidated Statements of
Operations
(Unaudited; dollars and shares
in millions, except per share data)
Three Months Ended
September 30,
FX Impact
Constant Currency
Increase (Decrease)
2023(1)
2022
Change $
Change %
Net revenue
$
982
$
1,022
$
18
$
(58
)
(6
)%
Cost of sales
801
764
14
23
3
%
Gross margin
181
258
4
(81
)
(32
)%
Selling, general, and administrative
expenses
215
196
3
16
8
%
Goodwill impairment charges
700
—
—
700
*
Other operating expense, net
1
2
—
(1
)
(18
)%
Operating (loss) earnings
(735
)
60
1
(796
)
*
Interest expense, net
58
32
—
26
80
%
Other expense, net
13
25
1
(13
)
(54
)%
(Loss) earnings before income taxes
(806
)
3
—
(809
)
*
Income tax (benefit) expense
(91
)
3
1
(95
)
*
Net loss
$
(715
)
$
—
$
(1
)
$
(714
)
*
Weighted average shares outstanding –
basic
181
180
Weighted average shares outstanding –
diluted
181
181
Earnings per share:
Basic
Net loss
$
(3.94
)
$
—
Diluted
Net loss
$
(3.94
)
$
—
(1)
Represents preliminary
results.
*
Not meaningful
Catalent, Inc.
Condensed Consolidated Balance
Sheets
(Unaudited; dollars in
millions)
September 30,
2023(1)
June 30,
2023(1)
ASSETS
Current assets:
Cash and cash equivalents
$
209
$
280
Trade receivables, net
826
977
Inventories
811
764
Prepaid expenses and other
795
658
Total current assets
2,641
2,679
Property, plant, and equipment, net
3,729
3,699
Other non-current assets, including
intangible assets
3,676
4,403
Total assets
$
10,046
$
10,782
LIABILITIES AND SHAREHOLDERS'
EQUITY
Current liabilities:
Current portion of long-term obligations
and other short-term borrowings
$
624
$
536
Accounts payable
367
427
Other accrued liabilities
552
544
Total current liabilities
1,543
1,507
Long-term obligations, less current
portion
4,322
4,313
Other non-current liabilities
276
325
Total shareholders' equity
3,905
4,635
Total liabilities and shareholders'
equity
$
10,046
$
10,782
(1)
Represents preliminary
results.
Catalent, Inc.
Condensed Consolidated
Statements of Cash Flows
(Unaudited; dollars in
millions)
Three Months Ended
September 30,
2023(1)
2022
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net cash used in operating activities
$
(70
)
$
(92
)
CASH FLOWS FROM INVESTING
ACTIVITIES:
Acquisition of property, equipment, and
other productive assets
(84
)
(149
)
Proceeds from maturity of marketable
securities
—
24
Proceeds from sale of property and
equipment
1
6
(Payments) proceeds for investments
(1
)
3
Net cash used in investing activities
(84
)
(116
)
CASH FLOWS FROM FINANCING
ACTIVITIES:
Proceeds from borrowing
115
75
Payments related to long-term
obligations
(35
)
(7
)
Financing fees paid
(1
)
—
Cash received, in lieu of equity, for tax
withholding obligations
—
2
Exercise of stock options
1
1
Other financing activities
18
3
Net cash provided by financing
activities
98
74
Effect of foreign currency exchange on
cash and cash equivalents
(15
)
(34
)
NET DECREASE IN CASH AND CASH
EQUIVALENTS
(71
)
(168
)
CASH AND CASH EQUIVALENTS AT BEGINNING
OF PERIOD
280
449
CASH AND CASH EQUIVALENTS AT END OF
PERIOD
$
209
$
281
(1)
Represents preliminary
results.
Catalent, Inc.
Reconciliation of Net Earnings
(Loss) to EBITDA from Operations and Adjusted EBITDA*
(Unaudited; dollars in
millions)
Three months ended
September 30,
2022
December 31,
2022
March 31,
2023
June 30,
2023(1)
September 30,
2023(1)
Net earnings (loss)
$
—
$
81
$
(227
)
$
(86
)
$
(715
)
Interest expense, net
32
47
51
54
58
Income tax expense (benefit)
3
33
(55
)
(64
)
(91
)
Depreciation and amortization
99
103
106
114
112
EBITDA (loss) from operations
134
264
(125
)
18
(636
)
Goodwill impairment charges
—
—
210
—
700
Stock-based compensation
19
10
6
—
19
Impairment charges and gain/loss on sale
of assets
(2
)
1
6
85
(1
)
Restructuring costs
4
23
9
30
2
Acquisition, integration, and other
special items
5
9
8
9
8
Foreign exchange loss (gain)
27
(26
)
(8
)
(4
)
9
Site transformation costs
—
—
—
—
14
Other adjustments
—
2
(1
)
1
—
Adjusted EBITDA
$
187
$
283
$
105
$
139
$
115
Favorable (unfavorable) FX impact
2
Adjusted EBITDA at constant currency
$
113
*
Refer to Catalent's description
of non-GAAP measures, including EBITDA from operations and Adjusted
EBITDA as referenced above.
(1)
Represents preliminary
results.
Catalent, Inc.
Reconciliation of Net Loss to
Adjusted Net (Loss) Income*
(Unaudited; dollars in
millions, except per share data)
Three months ended
September 30,
2022
December 31,
2022
March 31,
2023
June 30,
2023(10)
September 30,
2023(10)
Net earnings (loss)
$
—
$
81
$
(227
)
$
(86
)
$
(715
)
Amortization (1)
33
34
34
35
34
Goodwill impairment charges (2)
—
—
210
—
700
Stock-based compensation
19
10
6
—
19
Impairment charges and gain/loss on sale
of assets (3)
(2
)
1
6
85
(1
)
Restructuring costs (4)
4
23
9
30
2
Acquisition, integration, and other
special items (5)
5
9
8
9
8
Foreign exchange loss (gain)
27
(26
)
(8
)
(4
)
9
Site transformation costs(6)
—
—
—
—
14
Other adjustments
—
2
—
—
—
Estimated tax effect of adjustments
(7)
(19
)
(12
)
(12
)
(81
)
(21
)
Discrete income tax benefit items (8)
(6
)
—
(43
)
28
(68
)
Adjusted net (loss) income (ANI)
$
61
$
122
$
(17
)
$
16
$
(19
)
Weighted average shares outstanding –
basic
180
181
Weighted average shares outstanding –
diluted
181
181
Earnings per share:
Net loss per share – basic
$
—
$
(3.94
)
Net loss per share – diluted
$
—
$
(3.94
)
ANI per share:
ANI per share – basic
$
0.34
$
(0.10
)
ANI per share – diluted (9)
$
0.34
$
(0.10
)
* Refer to Catalent's description
of non-GAAP measures, including Adjusted Net Income as referenced
above.
(1)
Represents the amortization
attributable to purchase accounting for previously completed
business combinations.
(2)
Non-cash goodwill impairment
charges during the three months ended March 31, 2023 were
associated with the Company's Consumer Health reporting unit.
Non-cash goodwill impairment charges during the three months ended
September 30, 2023 were associated with the Company's Biomodalities
and Consumer Health reporting units.
(3)
For the three months ended June
30, 2023, represents fixed asset impairment charges primarily
associated with an idle facility in the Biologics segment.
(4)
Restructuring costs represent
employee and non-employee restructuring charges associated with
Catalent's plans to reduce costs, consolidate facilities, and
optimize its infrastructure across the organization.
(5)
Acquisition, integration and
other special items include costs associated with its October 2022
acquisition of Metrics Contract Services.
(6)
For the three months ended
September 30, 2023, represents operational and engineering
enhancements and costs related to a transformation program in our
Biologics segment.
(7)
The tax effect of adjustments to
Adjusted Net (Loss) Income is computed by applying the statutory
tax rate in the jurisdictions to the income or expense items that
are adjusted in the period presented; if a valuation allowance
exists, the rate applied is zero.
(8)
Discrete period income tax
expense items are unusual or infrequently occurring items,
primarily including: changes in judgment related to the
realizability of deferred tax assets in future years, changes in
measurement of a prior-year tax position, deferred tax impact of
changes in tax law, and purchase accounting.
(9)
For the three months ended
September 30, 2023 and 2022, represents Adjusted Net (Loss) Income
divided by the weighted average sum of fully diluted shares
outstanding, which is equal to (a) the number of shares of common
stock outstanding, plus (b) the number of shares of its common
stock that would be issued assuming exercise or vesting of all
potentially dilutive instruments. For the three months ended
September 30, 2023 and 2022, the weighted average number of shares
was 181 million.
(10)
Represents preliminary
results.
Catalent, Inc.
Reconciliation of Segment
EBITDA to Net Loss
(Unaudited; dollars in
millions, except per share data)
Three Months Ended
September 30,
2023(2)
2022
Biologics Segment EBITDA
$
52
$
113
Pharma and Consumer Health Segment
EBITDA
101
108
Sub-Total
$
153
$
221
Reconciling items to net loss
Goodwill impairment charges
$
(700
)
$
—
Unallocated costs, excluding goodwill
impairment charges (1)
(89
)
(87
)
Depreciation and amortization
(112
)
(99
)
Interest expense, net
(58
)
(32
)
Income tax benefit (expense)
91
(3
)
Net loss
$
(715
)
$
—
(1)
Unallocated costs include
restructuring and special items, stock-based compensation,
impairment charges, gain on sale of subsidiary, certain other
corporate directed costs, and other costs that are not allocated to
the segments.
(2)
Represents preliminary
results.
Catalent, Inc.
Calculation of Net Leverage
Ratio
(Unaudited; dollars in
millions)
September 30,
2022
December 31,
2022
March 31,
2023
June 30,
2023(1)
September 30,
2023(1)
Incremental Term Loan, due 2028
$
1,429
$
1,426
$
1,422
$
1,418
$
1,415
Revolving credit facility
75
600
550
500
585
Unamortized discount and debt issuance
costs
(7
)
(13
)
(12
)
(11
)
(12
)
Total Secured Debt
1,497
2,013
1,960
1,907
1,988
Senior Notes, due 2027, 5.000%
500
500
500
500
500
Senior Notes, due 2028 (EUR), 2.375%
794
879
895
904
872
Senior Notes, due 2029, 3.125%
550
550
550
550
550
Senior Notes due 2030, 3.500%
650
650
650
650
650
Finance Leases / Other
245
291
323
366
412
Unamortized discount and debt issuance
costs
(32
)
(30
)
(29
)
(28
)
(26
)
Total Unsecured Debt
2,707
2,840
2,889
2,942
2,958
Total Debt
4,204
4,853
4,849
4,849
4,946
Cash and Cash Equivalents
281
442
252
280
209
Marketable Securities
64
28
—
—
—
Total Net Debt
$
3,859
$
4,383
$
4,597
$
4,569
$
4,737
Adjusted EBITDA
Q2 2022
310
Q3 2022
339
339
Q4 2022
358
358
358
Q1 2023
187
187
187
187
Q2 2023
283
283
283
283
Q3 2023
105
105
105
Q4 2023
139
139
Q1 2024
115
LTM Adjusted EBITDA
$
1,194
$
1,167
$
933
$
714
$
642
First Lien Debt / Adj. EBITDA
1.2x
1.6x
2.2x
2.8x
3.4x
Net Sr. Secured Debt / Adj. EBITDA
1.0x
1.3x
1.8x
2.3x
2.8x
Net Debt / Adj. EBITDA
3.2x
3.8x
4.9x
6.4x
7.4x
(1)
Represents preliminary
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231114206805/en/
Investor Contact:
Catalent, Inc. Paul Surdez 732-537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Apr 2024 to May 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From May 2023 to May 2024